Abstract 5502: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy with Antiplatelet Following TAVR in Patients on Chronic Oral Anticoagulation
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.5502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Hoang Nhat Pham und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Optimal antithrombotic management following transcatheter aortic valve replacement (TAVR) in patients with pre-existing indications for chronic oral anticoagulation (OAC) remains poorly defined. Current evidence, including the POPular TAVI trial, suggests OAC monotherapy may be sufficient, yet combination therapy with antiplatelet remains common in clinical practice. We evaluated clinical outcomes of OAC monotherapy versus OAC combined with antiplatelet therapy in this high-risk population using a large real-world dataset.
Methods
We conducted a retrospective cohort study using the TriNetX Research Network (2020-2024) including adults on chronic OAC who underwent TAVR. Patients with prior valve replacement, rheumatic aortic stenosis, allergy to aspirin/clopidogrel, or coronary intervention within 3 months prior to TAVR were excluded. Patients were stratified into three cohorts based on antiplatelet use in the 3 months post-TAVR: OAC monotherapy, OAC + aspirin, and OAC + clopidogrel. Propensity score matching (1:1) was performed to balance baseline characteristics. Outcomes were assessed from TAVR through 1 year of follow-up. Hazard ratios (HR) were estimated using Cox proportional hazards regression. Statistical significance was defined as two-sided p
Zitieren
APA
Pham, H. N., Abdelnabi, M., Ibrahim, R., Ibrahim, S., Busch, S., Toliver, N., Monther, N., Western, A., & Singh, A. (2026). Abstract 5502: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy with Antiplatelet Following TAVR in Patients on Chronic Oral Anticoagulation. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.5502
Vancouver
Pham HN, Abdelnabi M, Ibrahim R, Ibrahim S, Busch S, Toliver N, et al. Abstract 5502: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy with Antiplatelet Following TAVR in Patients on Chronic Oral Anticoagulation. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.5502
BibTeX
@article{Pham2026,
author = {Pham, Hoang Nhat and Abdelnabi, Mahmoud and Ibrahim, Ramzi and Ibrahim, Sammudeen and Busch, Sarah and Toliver, Nellie and Monther, Noorhan and Western, Adam and Singh, Amitoj},
title = {Abstract 5502: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy with Antiplatelet Following TAVR in Patients on Chronic Oral Anticoagulation},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.5502}
}
EUVIMED